Radiopharmaceutical dosimetry: a means to optimize and monitor molecular radiotherapy  
Manuel Bardiès, PhD
Manuel Bardiès obtained his Doctorate on radiopharmaceutical dosimetry (with distinction) from Paul Sabatier University (Toulouse III) in November 15, 1991. He has been developing his research in radiopharmaceutical dosimetry within INSERM since 1991, in Nantes then in Toulouse.
Under his responsibility:
  - 10 PhD dissertations have been defended since 2000
  - 2 PhD projects are ongoing
  - 2 PhD projects are ongoing under the form of a co-supervision
  - Master training: about 30 Master student projects since 1995
  - Other training (Engineering students): about 20 students since 1996
  - Several academic or industrial projects have been funded and involved recruiting Post-Doctoral scientists.
  - Manuel Bardiès has authored or participated to more than 60 articles referenced in MedLine.
The team led by Manuel Bardiès in Toulouse is primarily involved in radiopharmaceutical dosimetry, at various scales (cell, tissue, organ). This requires the ability to assess radiopharmaceutical pharmacokinetics in vivo, through quantitative SPECT or PET small-animal imaging. An important part of research activity is related to Monte-Carlo modeling of radiation transport through biologic structures of interest, in order to give account of energy deposition within tumor targets – or conversely critical non-tumor tissues/organs. The objective is to improve molecular radiotherapy by allowing patient-specific treatments (personalized medicine).
  Targeted radionuclide therapy combined with immunotherapy in a head and neck cancer mouse model  
Amber Bates  
  Analytical models for microdosimetry to calculate dose from alpha-emitters used in radioimmunotherapy  
Alejandro Bertolet  
  Naturally occurring cancers in companion animals offer more realistic models for evaluation of nuclear imaging and therapy  
Jeffrey Bryan  
  Design and simulation of a novel positron detector to measure the AIF for dynamic PET  
Liam Carroll  
  Radiolabeling, isotopes and radiation quality effects  
Sarah Cheal, PhD
Dr. Cheal's research focuses on the development of a theranostic platform approach for pretargeted radioimmunotherapy (PRIT) of solid human tumors. The lab at Memorial Sloan Kettering Cancer Center calls this strategy “DOTA-PRIT,” which is short for “DOTA ligand bound radionuclide-based pretargeted radioimmunotherapy.” In principle, DOTA-PRIT consists of three sequential administrations of three reagents: (i) the bi-specific Ab construct IgG-scFv (bsAb), which has high specificity and affinity for both a tumor antigen through the IgG and a radiolabeled hapten through the scFv; (ii) a clearing agent to eliminate unbound construct from the blood; and (iii) the imaging/therapeutic radioligand. The tumor targeting is separated from the payload-delivery step, thereby offering greater therapeutic indices (TIs) compared to conventional radioimmunodetection/radioimmunotherapy with directly labeled antibodies. Significant improvement in TIs permits high therapeutic doses of administered radioisotopes with minimal to no bystander side effects. In close collaboration with the lab of Nai-Kong Cheung at MSK and Dane Wittrup at MIT, they have successfully applied this platform in three preclinical tumor models: GPA33 antigen (colorectal cancer); GD2 antigen (neuroblastoma); and the HER2/neu receptor (breast cancer).
  A novel radio-magnetic-nanoplatform for theranostics  
Yaser Gholami  
  Small scale modeling for radiopharmaceutical dosimetry  
Robert Hobbs, PhD
Dr. Robert Hobbs is an Assistant Professor in the Johns Hopkins Medicine Department of Radiology and Radiological Science and a member of the Johns Hopkins Kimmel Cancer Center. He earned his PhD in experimental high-energy physics from the University of New Mexico. Dr. Hobbs joined Johns Hopkins in 2006.
Dr. Hobbs' research focuses on dosimetry, which measures and calculates the radiation dose received by matter and tissue that has been exposed to radiation. His current studies examine various radiobiologic modeling techniques for treatment of specific tumors and cancers. Dr. Hobbs is also developing an alpha-particle dosimetry model that can examine alpha particles which are hard to study with current imaging modalities.
Dr. Hobbs is a member of the Radionuclide Therapy and Dosimetry (RTD) Research Lab, where he performs tail vein injections and bio-distribution, and provides assistance to Dr. Hong Song. He is engaged in research that examines how tumor burden and prior chemotherapy affects bone marrow dosimetry.

  Radiation dosimetry and biology of radionuclides: their challenges and their key roles in optimizing radiopharmaceutical therapy  
Roger Howell, PhD
Roger Howell, PhD, is a Professor of Radiology at Rutgers New Jersey Medical School where he serves as Chief of the Division of Radiation Research. Dr. Howell’s laboratory conducts research on dosimetry and radiobiology of internal radionuclides, with emphasis on the microscopic dose distributions encountered in nuclear medicine. He also studies the capacity of vitamins and other natural agents to protect reproductive organs, bone marrow, and the gastrointestinal tract against damage caused by ionizing radiation.
These efforts have led to over 100 publications in peer-reviewed journals. Dr. Howell teaches physics to radiology residents and provides educational lectures for emergency responders in New Jersey. He has served on review panels for federal agencies including the National Institutes of Health, the U.S. Department of Energy, and other organizations. Dr. Howell is a member of the Medical Internal Radiation Dose Committee of the Society of Nuclear Medicine and Molecular Imaging, He has served on several report committees of the International Commission on Radiation Units and Measurements (ICRU) and was elected to the ICRU Main Commission in May 2014. Dr. Howell earned his BS and PhD in Physics from the University of Massachusetts, Amherst.
  Clinical trials with Ra-224  
Aron Popovtzer, PhD

 Key considerations: Driving adoption of your theranostics

Olga Koper, PhD 
Olga Koper serves as Senior Director of Business Development at Cardinal Health Nuclear & Precision Health Solutions. She has 25 years of experience leading multidisciplinary teams, overseeing commercial and government projects, liaising with clients to better address their needs, and transferring technology to develop cross-industry solutions.  In her current role, she focuses on developing partnerships with companies, academia and governmental agencies in precision health, particularly in theranostics.
Prior to joining Cardinal Health, she worked at Battelle Memorial Institute overseeing energy-related business development and sales, and in a nanotechnology start-up, commercializing technologies from Kansas State University. Olga has designed nanomaterials for cancer detection and treatment, water and air filtration, biomass conversion, and decontamination of toxic chemicals and biological species. These activities resulted in over 30 issued U.S. and international patents and 35 peer-reviewed publications. 
Olga received an M.S. in General Chemistry from Silesian University in Poland and a Ph.D. from Kansas State University, where she holds an adjunct professor position. She was selected as an Immigrant Innovator “Champion of Change” by the White House and an “Outstanding American by Choice” by U.S. Immigration and Naturalization Services.

  Patient studies with Lu/Ac  
Daniel Juneau, MD, FRCPC
Daniel Juneau, MD, FRCPC, is an investigative researcher at the CHUM Research Center in Montreal with a focus in imaging and engineering. He is also a specialist in nuclear medicine in the department of nuclear medicine at CHUM, a clinical assistant professor in the department of medicine at the University of Montreal and an affiliated researcher at the University of Ottawa Heart Institute.
Dr. Juneau's research interests include:
- Quantification of the myocardial flow and the flow reserve.
- PSMA imaging in prostate cancer.
- Treatment of solid cancers with radiopharmaceuticals (alpha and beta emitters).
- Imaging of infectious diseases of the heart.
- Imaging of infiltrative and inflammatory diseases of the cardiovascular system.

Henry VanBrocklin, PhD
Dr. VanBrocklin is Professor of Radiology and Biomedical Imaging at the University of California San Francisco (UCSF) and Director of Radiopharmaceutical Research in the Center for Functional and Molecular Imaging. His work in the field spans many radiopharmaceutical science disciplines from short-lived radioisotope production to the creation of fluorine-18 and carbon-11 labeling chemistry strategies for new radiotracer preparation and application. His current research interests include design of imaging agents targeting cancer cell surface markers, development of new strategies for labeling biomolecules with imaging and therapeutic isotopes, preparation of probes for neurodegenerative disorders including ALS, the application of imaging in drug development and elaboration of zirconium-89 labeled antibodies for various applications including rheumatoid arthritis and HIV reservoir detection. Dr. VanBrocklin oversees a state-of-the-art radiochemistry, imaging, and training facility at UCSF for basic R&D and preclinical studies as well as clinical applications. He is Immediate Past-President of Society of Radiopharmaceutical Sciences.

Dr. VanBrocklin received his Ph.D. (1990) in Radiopharmaceutical Chemistry from Washington University St. Louis under the mentorship of Prof. Michael Welch.  He furthered the development of positron-labeled estrogens, progestins and androgens for tumor imaging. As a US Department of Energy Alexander Hollander Distinguished Postdoctoral Fellow (1990-92) he continued his research on positron labeled steroids and fatty acids in the laboratory of Prof. John Katzenellenbogen at the University of Illinois. In 1992 Dr. VanBrocklin joined Lawrence Berkeley National Laboratory as Staff Scientist and Radiopharmaceutical Chemistry Group Leader in the Department of Functional Imaging prior to moving to UCSF in 2005.

Charles Maitz, DVM, PhD
Charles Maitz, DVM, PhD, is an assistant professor of radiation oncology at the University of Missouri College of Veterinary Medicine. Dr. Maitz holds a joint position with the School of Medicine’s Department of Radiology and the International Institute of Nano and Molecular Medicine. Dr. Maitz earned both his DVM and Ph.D. at the University of Missouri.
He has strong interests in clinical radiation therapy, comparative medicine, radiation biology and radiation dosimetry. He has had a research focus in boron neutron capture therapy, as well as in neutron dosimetry and computational dose modeling. Much of this research uses Monte Carlo based computer modeling using Geant4 and Gate. This gives him a very basic familiarity with C++ and the RHEL shell.

  Preclinical studies of targeted radionuclide therapy and radiosensitization strategies for cancer therapy  
Marika Nestor, MD, PhD
Marika Nestor leads a translational research group at the Department of Immunology, Genetics and Pathology, Uppsala University, Sweden. Her research group focuses on radionuclide targeting and radiosensitization of cancer cells. She obtained her PhD in 2006, and became an Associate Professor in 2012. In 2013 she was awarded the Göran Gustafsson prize for young scientists, and in 2016 she received the Junior Investigator Award from the Swedish Cancer Society. She holds research grants from e.g. the Swedish Research Council, the Swedish Cancer Society and The Swedish Radiation Safety Authority. In 2019, she was awarded a grant from Sweden’s innovation agency VINNOVA to facilitate clinical translation of her findings.
  Immune Effects  
Ravi Patel, MD, PhD
Dr. Patel is a Bentson Radiation Oncology Research Fellow in the Department of Human Oncology at the University of Wisconsin- Madison. He has an MD and PhD in biomedical engineering from Case Western University. He is pursuing a career as physician-scientist and one day hopes to have his own lab. He currently works in the Morris Lab, where he applies his expertise in mathematical modeling, drug delivery and in situ vaccination to a variety of research projects. One project looks at targeting metastatic disease through a combination of killing suppressive immune cells and using systemic immunotherapy agents. An exciting aspect about immunotherapy is that it could potentially work on a variety of cancers. Cancer has the ability to evade the immune system, so if we can figure out how to activate the immune system to recognize someone’s cancer, he thinks we can use those concepts on a wide variety of tumors.
  Radiometals and chelators: How we got here and where we’re going 

Eric W. Price, PhD
After completing a B.Sc. in Chemistry at University of Victoria (2003-2009), Eric obtain a Ph.D. in Vancouver with Prof. Chris Orvig (UBC) and Dr. Michael Adam (TRIUMF) in (2009-2014) on the design and synthesis of chelators for radiometals. Dr. Price then moved to New York City to work as a postdoctoral fellow under Dr. Jason S. Lewis at Memorial Sloan Kettering Cancer Center (MSKCC), where he expanded his skillset in radiochemistry and molecular imaging. Dr. Price then moved to the University of Saskatchewan in 2016 as an Assistant Professor of Chemistry and Canada Research Chair in Radiochemistry. His growing research program is very multidisciplinary and is creating new chemical tools and improving existing chemical methods to advance molecular imaging and radionuclide therapy. This focus includes new chelators to bind with a variety of radioactive metals, designing and synthesizing new near-infrared dyes, cyclotron production and purification of radiometals, improving existing methods and also developing new methods for bioconjugation reactions, optimizing and rethinking existing radiochemistry reactions, and creating modular and functional linkers to enhance and optimize existing radiopharmaceuticals. 

  Lipid raft mediated effects of Auger and alpha targeted radionuclide therapy: role of cholesterol metabolism  
Jean Pierre Pouget, PhD
Dr. Jean-Pierre Pouget obtained his PhD thesis in Radiobiology in 2000 from the Curie Institute in Paris and carried-out a post-doctoral fellowship in the Nuclear Medicine Research Laboratory at Barts and the London School of Medicine and Dentistry. He then moved to Paris to the French Radiation Protection and Nuclear Safety Agency (IRSN) for 4 years where he worked on radiation casualties. After moving to Montpellier, he joined the French National Institute for Health and Medical research (INSERM) where he is now leader of the Radiobiology and Targeted Radiotherapy team at the Cancer Research Institute of Montpellier (INSERM, France). He develops new radiopharmaceuticals for cancer imaging and therapy with a special focus on radiobiology. He has published about 50 papers dealing with radiobiology and radionuclide therapy and several patents. Besides research activity, Dr Pouget is involved in teaching at the University of Montpellier.
  Development and optimization of prostate-specific membrane antigen-targeted radionuclide therapy  
Scott Tagawa, MD, MS
Scott T. Tagawa, MD, MS is the Richard A. Stratton Associate Professor in Hematology and Oncology, an Associate Professor of Clinical Medicine & Urology at Weill Cornell Medicine, and an Associate Attending Physician at NewYork-Presbyterian – Weill Cornell Medical Center.
After earning his BS from Georgetown University, Dr. Tagawa received his MD at the University of Southern California School of Medicine. After completing his Internship and Residency training there, he became Chief Resident and subsequently underwent fellowship training in Hematology and Medical Oncology, being appointed Chief Fellow for his final two years. He had the opportunity to train with international leaders in Genitourinary (GU) Oncology. In August 2005, he was appointed Assistant Professor of Medicine at Mount Sinai School of Medicine, serving as Associate Program Director for the Fellowship Training Program. As Director of Genitourinary Oncology for the Division of Hematology and Oncology and Director of Medical Oncology for the Deane Prostate Health and Research Center, Dr. Tagawa took the lead in developing genitourinary clinical trials. He was recruited to Weill Cornell Medical College in 2007. His research covers clinical and translational investigations in genitourinary tumors and thrombosis in malignancy. As the Medical Director of the Genitourinary Oncology Research Program, Dr. Tagawa leads clinical trials in the areas of prostate, kidney, and bladder cancer as well as the prevention and treatment of thrombosis with cancer. He specializes in drug development and theranostics in prostate cancer.

  An Update on the NCI CTEP Radiopharmaceutical Portfolio   
Charles Kunos, MD, PhD
Charles Kunos, MD, PhD, is a Medical Officer in the Investigational Drug Branch (IDB) of the Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment and Diagnosis (DCTD) at the NCI and oversees adult and pediatric investigational therapeutics alone or in combination with radiation therapy. He received his medical and doctorate degrees from Case Western Reserve University School of Medicine in Cleveland, Ohio. He undertook radiation oncology training at the NCI-designated Case Comprehensive Cancer Center at University Hospitals of Cleveland. He then became the Clinical Director of the Gynecologic, Pediatric, and Musculoskeletal radiation therapy at University Hospitals of Cleveland. During his tenure, he developed skills in conventional radiotherapy, gynecologic brachytherapy, helical tomotherapy, gamma knife radiosurgery, and cyberknife stereotactic body radiosurgery. During this same time, he ran a radiobiology laboratory focused on the science of ribonucleotide reductase and its pharmacological inhibition by triapine using uterine cervix cancer preclinical models. He was the principal investigator for the NCI-sponsored phase I and II clinical trials of triapine radiochemotherapy for women with advanced stage uterine cervix cancer, which demonstrated very high overall response rates and progression-free survival. He was formerly the NCI Gynecologic Oncology Group’s liaison for Radiation Medicine, serving on multiple committees and task forces as well as serving as a Phase I co-chair of the Developmental Therapeutics Committee between 2012 and 2015.

Dr. Kunos joined NCI in 2016. He provides scientific review, develops and implements clinical trials, and monitors adverse events for a diverse drug portfolio involving experimental therapeutic agents that manipulate DNA damage responses by themselves or in combination with radiation therapy. He led NCI’s team that was granted Food & Drug Administration Orphan Drug Designation and Fast Track Designation for triapine in combination with cisplatin-radiation therapy for treatment of women with advanced stage uterine cervix cancer. He received a 2018 NCI Director’s Award for leading a team that improved uterine cervix cancer patient clinical trial access within Puerto Rico’s NCI Community Oncology Research Program (NCORP). He currently directs CTEP’s IDB Fellow and Early Career Investigator Externship Program and its educational efforts to improve written communication in CTEP’s Letters of Intent (LOIs). He also interacts with other NCI branches/programs as well as with other Federal Agencies to leverage resources in a first-ever CTEP clinical development program for radiopharmaceuticals.

  Combination therapies  
Katherine Vallis
Dr. Katherine Vallis undertook specialist training in Clinical Oncology at the Hammersmith Hospital and doctoral research at Edinburgh University. In 1995 she was appointed as Staff Radiation Oncologist at the Princess Margaret Hospital and Scientist at the Ontario Cancer Institute, Toronto. She returned to the UK in 2006 to join the Oxford Institute and establish the Radiotherapeutics and Radioimaging Group.
Her lab's research is in personalising radiotherapy using functional imaging. They apply functional and molecular imaging techniques to developing radiotherapy personalised to each patients’ individual tumour biology.

  Investigating the self-calibration factor for 90Y SPECT/CT image-based dosimetry  
S. Peter Kim
  Effect of Dose Rate Patterns on Expression of Immune Markers on the Surface of Breast Cancer Cells  
Calvin Leung
  Development of 211At production via continuous extraction of 211Rn  
Jerry Nolen  
  Molecular Radiotherapy: Future Challenges and Opportunities with Alpha Emitters  
Kevin Prise

Kevin Prise is Professor of Radiation Biology, at the Patrick G Johnston Centre for Cancer Research at Queen’s University Belfast. He has developed wide-ranging interests in radiation biology including research on low dose radiation risk, radiation quality, cell and tissue signalling mechanisms. His recent work, at Queen’s has involved the development of an Advanced Radiotherapy Group (ARG) integrating Radiation Oncology and Clinical Radiotherapy Physics with Translational Radiation Biology.  Together they are developing new biological based models for optimising advanced radiotherapies such as Intensity Modulated Radiotherapy, molecular radiotherapies and particle therapies. A current focus is on the development of new technologies for the precision delivery of particle therapies and optimization based on biologically driven relative biological effectiveness models.

Prof Prise received his PhD in Cell Biology and Biochemistry, from the University of Aberdeen, on the mechanisms of action of the chemotherapeutic methotrexate. He joined the Gray Laboratory, in Northwood London, in 1985 working with Barry Michael, Melvyn Folkard and Boris Vojnovic, under the directorships of Jack Fowler, Julie Denekamp and Ged Adams. He became Head of the Cell and Molecular Radiation Biology Group at the Gray Laboratory prior to joining Queen’s University Belfast in 2007.

  Are you a speaker? Looking for information? Contact Audrey by email at audrey@radres.org or by phone at 877.216.1919.  

380 Ice Center Lane, Suite C | Bozeman, MT 59718 | 1.877.216.1919
Member & Exhibitor Services: Audrey Rinehart |
1.877.216.1919  |  audrey@radres.org